Fushen Sha

418 total citations
6 papers, 113 citations indexed

About

Fushen Sha is a scholar working on Genetics, Pathology and Forensic Medicine and Neurology. According to data from OpenAlex, Fushen Sha has authored 6 papers receiving a total of 113 indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Genetics, 3 papers in Pathology and Forensic Medicine and 2 papers in Neurology. Recurrent topics in Fushen Sha's work include Chronic Lymphocytic Leukemia Research (3 papers), Lymphoma Diagnosis and Treatment (3 papers) and CNS Lymphoma Diagnosis and Treatment (2 papers). Fushen Sha is often cited by papers focused on Chronic Lymphocytic Leukemia Research (3 papers), Lymphoma Diagnosis and Treatment (3 papers) and CNS Lymphoma Diagnosis and Treatment (2 papers). Fushen Sha collaborates with scholars based in China, United States and Spain. Fushen Sha's co-authors include Paul A. Hamlin, Steven M. Horwitz, Andrew D. Zelenetz, David J. Straus, Ariela Noy, Anas Younes, Alison J. Moskowitz, Carol S. Portlock, Anita Kumar and Matthew J. Matasar and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood Cancer Journal.

In The Last Decade

Fushen Sha

6 papers receiving 112 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Fushen Sha China	4	75	68	44	25	13	6	113
Gerard Frigola Spain	6	44 0.6×	56 0.8×	26 0.6×	31 1.2×	23 1.8×	14	127
Yazeed Sawalha United States	8	99 1.3×	97 1.4×	53 1.2×	24 1.0×	10 0.8×	43	169
M. Ponzoni Switzerland	2	103 1.4×	73 1.1×	49 1.1×	11 0.4×	9 0.7×	2	114
Jesse Shustik Canada	5	114 1.5×	78 1.1×	50 1.1×	26 1.0×	16 1.2×	11	142
Barbara Mankel Germany	6	76 1.0×	72 1.1×	36 0.8×	43 1.7×	10 0.8×	12	131
David Šálek Czechia	8	130 1.7×	102 1.5×	44 1.0×	30 1.2×	27 2.1×	23	156
Carlo Sagramoso Italy	7	57 0.8×	37 0.5×	29 0.7×	10 0.4×	8 0.6×	11	86
Allison Barraclough Australia	8	106 1.4×	87 1.3×	30 0.7×	19 0.8×	21 1.6×	29	152
Farheen Mir United Kingdom	6	109 1.5×	74 1.1×	25 0.6×	46 1.8×	18 1.4×	13	167
Julia González‐Rincón Spain	5	73 1.0×	53 0.8×	32 0.7×	19 0.8×	3 0.2×	7	106

Countries citing papers authored by Fushen Sha

Since Specialization

Citations

This map shows the geographic impact of Fushen Sha's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fushen Sha with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fushen Sha more than expected).

Fields of papers citing papers by Fushen Sha

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fushen Sha. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fushen Sha. The network helps show where Fushen Sha may publish in the future.

Co-authorship network of co-authors of Fushen Sha

This figure shows the co-authorship network connecting the top 25 collaborators of Fushen Sha. A scholar is included among the top collaborators of Fushen Sha based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fushen Sha. Fushen Sha is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

6 of 6 papers shown

1.

Li, Zhiyang, Xin Wu, Yanjie Zhao, et al.. (2021). Clinical benefit of neoadjuvant anti‐PD‐1/PD‐L1 utilization among different tumors. SHILAP Revista de lepidopterología. 2(1). 60–68. 22 indexed citations

2.

Xiao, Yinan, Hanyue Xu, Wen Guo, et al.. (2020). Update on treatment and preventive interventions against COVID-19: an overview of potential pharmacological agents and vaccines. Molecular Biomedicine. 1(1). 16–16. 4 indexed citations

3.

Ghione, Paola, Erel Joffe, Sarah Noor, et al.. (2020). Alternative anti-CD20 antibody versus desensitization for lymphoma patients with drug hypersensitivity reactions requiring discontinuation of rituximab, obinutuzumab, or ofatumumab.. Journal of Clinical Oncology. 38(15_suppl). 8062–8062. 3 indexed citations

4.

Kumar, Anita, Fushen Sha, Ahmed Toure, et al.. (2019). Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse. Blood Cancer Journal. 9(6). 50–50. 76 indexed citations

5.

Huang, He, Zhao Wang, Xiaojie Fang, et al.. (2018). Randomized, open-label, phase Ⅱ trial of everolimus versus thalidomide in patients achieving remission after first-line therapy for high-risk diffuse large B-cell lymphoma.. Journal of Clinical Oncology. 36(15_suppl). 7560–7560. 1 indexed citations

6.

Sha, Fushen, et al.. (2014). miR-183 potentially inhibits NF-κB1 expression by directly targeting its 3′-untranslated region. Acta Biochimica et Biophysica Sinica. 46(11). 991–996. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact